Said Bouseida

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Peritoneal Dialysis

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)
Neil H Segal, Ignacio Melero Bermejo, Victor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, Maria E Rodriguez-Ruiz, Joseph P Eder, Cathy Eng, Gulam A Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nature communications 15 (1) (2024)